Anna Pawłowska-Łachut

Dr. Anna Pawłowska-Łachut

Independent Laboratory of Cancer Diagnostics and I, Medical University of Lublin, Lublin, Lubelskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
YBYingjie Bian
Yingjie Bian
WLWei Li
Wei Li
DKDaniel M. Kremer
Daniel M. Kremer
PSPeter Sajjakulnukit
Peter Sajjakulnukit
SLShasha Li
Shasha Li
WZWeiping Zou
Weiping Zou

Verified
Journal Article
Open access
PDF file
APAnna Pawłowska-Łachut
Anna Pawłowska-Łachut
ARAnna Rekowska
Anna Rekowska
WKWeronika Kuryło
Weronika Kuryło
APAnna Pańczyszyn
Anna Pańczyszyn
JKJan Kotarski
Jan Kotarski
Iwona WertelIwona Wertel
Iwona Wertel
The standard treatment of ovarian cancer (OC) patients, including debulking surgery and first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority (~70%) of patients with advanced OC. Clinical trials have shown only a modest (10–15%) response of OC individuals to treatment based on immune checkpoint inhibitors (ICIs). The resistance of OC to therapy is caused by various factors, including OC heterogeneity, low density of tumor-infiltrating lymphocytes (TILs), non-cellular and cellular interactions in the tumor microenvironment (TME), as well as a network of microRNA regulating immune checkpoint pathways. Moreover, ICIs are the most efficient in tumors that are marked by high microsatellite instability and high tumor mutation burden, which is rare among OC patients. The great challenge in ICI implementation is connected with distinguishing hyper-, pseudo-, and real progression of the disease. The understanding of the immunological, molecular, and genetic mechanisms of OC resistance is crucial to selecting the group of OC individuals in whom personalized treatment would be beneficial. In this review, we summarize current knowledge about the selected factors inducing OC resistance and discuss the future directions of ICI-based immunotherapy development for OC patients.

21 February 2020 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
MBMonika Bilska
Monika Bilska
APAnna Pawłowska-Łachut
Anna Pawłowska-Łachut
EZEwelina Zakrzewska
Ewelina Zakrzewska
ACAgata Chudzik
Agata Chudzik
DSDorota Suszczyk
Dorota Suszczyk
Iwona WertelIwona Wertel
Iwona Wertel
Ovarian cancer (OC) is usually diagnosed at an advanced stage and is related with poor prognosis. Despite numerous studies, the pathogenesis of OC is still unknown. Recent studies indicate the role of the immune system in the development and spread of OC. The identification of factors and mechanisms involved in that process and their modulation is crucial for creating effective antitumor therapy. We investigated the potential role of Th17 cells in OC patients (n = 71) by analyzing the frequencies of Th17 cells in three different environments, i.e., peripheral blood (PB), peritoneal fluid (PF), and tissue (Th17 infiltrating cells), and the concentration of IL-17A in plasma and PF of patients in terms of their clinical and prognostic significance. Th17 cells were analyzed by flow cytometry as a percentage of CD4+ lymphocytes that expressed intracellular expression of IL-17A. The level of IL-17A in plasma and PF were determined by ELISA. Our results showed accumulation of Th17 cells among tumor-infiltrating CD4+ lymphocytes (p<0.001 in relation to PB). Moreover, the percentage of Th17 cells in both PB and PF of OC patients was significantly lower than that in benign tumors group (n = 35). There were no significant differences in the percentage of Th17 cells in PB, PF, and tissue in relation to clinicopathological characteristics of OC patients and survival. The lower percentage of Th17 cells in the PB and PF of OC patients may promote evasion of host immune response by cancer cells. The concentration of IL-17A in plasma of OC patients was higher (p<0.0001) than that in both benign tumors and control group (n = 10). The PF IL-17A level in OC patients was higher (p<0.0001) than that in women with benign ovarian tumors, indicating its synthesis in OC microenvironment. Higher IL-17A level in PF is correlated with longer (median: 36.5 vs. 27 months) survival of OC patients.

21 January 2019 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
APAnna Pawłowska-Łachut
Anna Pawłowska-Łachut
DSD Suszczyk
D Suszczyk
KOKarolina Okła
Karolina Okła
BBBartłomiej Barczyński
Bartłomiej Barczyński
JKJ Kotarski
J Kotarski
IWI Wertel
I Wertel
Summary: Immunotherapies based on anti-programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway inhibitors may turn out effective in ovarian cancer (OC) treatment. They can be used in combination with standard therapy and are especially promising in recurrent and platinum-resistant OC. There is growing evidence that the mechanism of the PD-1/PD-L1 pathway can be specific for a particular histological cancer type. Interestingly, the data have shown that the PD-1/PD-L1 pathway blockade may be effective, especially in the endometrioid type of OC. It is important to identify the cause of anti-tumor immune response suppression and exclude its other mechanisms in OC patients. It is also necessary to conduct subsequent studies to confirm in which OC cases the treatment is effective and how to select patients and combine drugs to improve patient survival.

Verified
Journal Article
Open access
PDF file
APAnna Pawłowska-Łachut
Anna Pawłowska-Łachut
AKAgnieszka Kwiatkowska
Agnieszka Kwiatkowska
DSDorota Suszczyk
Dorota Suszczyk
ACAgata Chudzik
Agata Chudzik
RTRafał Tarkowski
Rafał Tarkowski
Iwona WertelIwona Wertel
Iwona Wertel
The latest literature demonstrates the predominant role of the programmed cell death axis (PD-1/PD-L1/PD-L2) in ovarian cancer (OC) pathogenesis. However, data concerning this issue is ambiguous. Our research aimed to evaluate the clinical importance of PD-L1/PD-L2 expression in OC environments. We evaluated the role of PD-L1/PD-L2 in OC patients (n = 53). The analysis was performed via flow cytometry on myeloid (mDCs) and plasmacytoid dendritic cells (pDCs) and monocytes/macrophages (MO/MA) in peripheral blood, peritoneal fluid (PF), and tumor tissue (TT). The data were correlated with clinicopathological characteristics and prognosis of OC patients. The concentration of soluble PD-L1 (sPD-L1) and PD-1 in the plasma and PF were determined by ELISA. We established an accumulation of PD-L1+/PD-L2+ mDCs, pDCs, and MA in the tumor microenvironment. We showed an elevated level of sPD-L1 in the PF of OC patients in comparison to plasma and healthy subjects. sPD-L1 levels in PF showed a positive relationship with Ca125 concentration. Moreover, we established an association between higher sPD-L1 levels in PF and shorter survival of OC patients. An accumulation of PD-L1+/PD-L2+ mDCs, pDCs, and MA in the TT and high sPD-L1 levels in PF could represent the hallmark of immune regulation in OC patients.

23 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
APAnna Pawłowska-Łachut
Anna Pawłowska-Łachut
WSWiktoria Skiba
Wiktoria Skiba
DSDorota Suszczyk
Dorota Suszczyk
WKWeronika Kuryło
Weronika Kuryło
JJJoanna Jakubowicz-Gil
Joanna Jakubowicz-Gil
Iwona WertelIwona Wertel
Iwona Wertel
The prognosis for ovarian cancer (OC) patients is poor and the five-year survival rate is only 47%. Immune checkpoints (ICPs) appear to be the potential targets in up-and-coming OC treatment. However, the response of OC patients to immunotherapy based on programmed cell death pathway (PD-1/PD-L1) inhibitors totals only 6–15%. The promising approach is a combined therapy, including other ICPs such as the T-cell immunoglobulin and ITIM domain/CD155/DNAX accessory molecule-1 (TIGIT/CD155/DNAM-1) axis. Preclinical studies in a murine model of colorectal cancer showed that the dual blockade of PD-1/PD-L1 and TIGIT led to remission in the whole studied group vs. the regression of the tumors with the blockade of a single pathway. The approach stimulates the effector activity of T cells and NK cells, and redirects the immune system activity against the tumor. The understanding of the synergistic action of the TIGIT and PD-1/PD-L1 blockade is, however, poor. Thus, the aim of this review is to summarize the current knowledge about the mode of action of the dual TIGIT and PD-1/PD-L1 blockade and its potential benefits for OC patients. Considering the positive impact of this combined therapy in malignancies, including lung and colorectal cancer, it appears to be a promising approach in OC treatment.